At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 955 enrolled
Drug / intervention
Tranexamic Aciddrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Double-blinded Trial to Explore the Optimum Dose of Tranexamic Acid in Cardiopulmonary Bypass Cardiac Surgery
In Brief
A Phase 4 clinical trial evaluating Tranexamic Acid for C.Surgical Procedure; Cardiac. Completed, enrolled 955 participants across 1 site.
Detailed Summary
Tranexamic acid, an antifibrinolytic drug, is wildly used in cardiac surgeries to decrease perioperative bleeding and allogenic transfusion. But the optimum dose of tranexamic acid is still unknown. We use three different doses to find which is the optimum dose of tranexamic acid in cardiopulmonary bypass cardiac surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsC.Surgical Procedure; Cardiac
CountriesChina
Collaborators--
Timeline
Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2012
First PostedNov 2013
Primary CompletionSep 2014
TodayJul 2026
First PostedNov 28, 2013
Enrollment StartSep 1, 2012
Primary CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 12.6 years ago
Interventions
Tranexamic Aciddrug
The loading doses were given in 15 minutes when incision.